

## MEDIA SUMMARY REPORT

## HEALTH ISSUE

**Media** : Jurnal Nasional  
**Page** : 5  
**Circulation** : 45,000

**Date** : 27 August 2013  
**DoS** : 27 August 2013  
**Tone** : Neutral

**Ovarian Cancer Early Detection**

Ovarian tumour is difficult to detect in its early phase but a study in USA tested on 4,051 women found a method that may detect early ovarian cancer. Over 90 percent recovery can be reached if ovarian cancer is detected earlier. There is no specific symptom of ovarian cancer. A certain protein called CA125 may signal the disease and its level is higher among individuals with ovarian cancer, although it is not reliable. Further study is needed to give more concrete result on ovarian cancer diagnosis.

**Person quoted (s):** Karen Lu, researcher  
Sarah Blagden, researcher at Centre for Ovarian Cancer Research

## PHARMACEUTICAL INDUSTRY AND GOVERNMENT POLICY

**Media** : Kontan  
**Page** : 5  
**Circulation** : 70,000

**Date** : 27 August 2013  
**DoS** : 27 August 2013  
**Tone** : Neutral

**PT KAEF Receives Loan Commitment Worth Rp1.3 Trillion**

PT Kimia Farma Tbk (KAEF) has received new loan commitment worth Rp1.3 trillion from a foreign bank, said Djoko Rusdianto, Corporate Secretary for PT KAEF. The amount is sufficient for KAEF business expansion until 2014 to anticipate the implementation of Social Security Administrative Body (BPJS) beginning in January 2014. PT KAEF decided to modify its expansion plan by building Banjaran plant instead. Earlier, PT KAEF needs Rp400 billion to build Pulogadung plant compared to Banjaran plant with Rp700 billion. In addition, PT KAEF will issue corporate bonds worth Rp1 trillion and the company currently has AA- rate from Pefindo. PT KAEF needs better strategy as SOE restructuring (merging PT KAEF with PT INAF) is still in progress in the Parliament. Therefore, PT KAEF must hold its new rights issue whereas the company has had rights issue permit since January 2012. PT KAEF targets Rp700 billion funding from rights issue.

**Person quoted (s):** Djoko Rusdianto, Corporate Secretary, PT KAEF

---

**Media** : Kontan  
**Page** : 13  
**Circulation** : 70,000

**Date** : 27 August 2013  
**DoS** : 27 August 2013  
**Tone** : Neutral

### **Indofarma Reorganizes Business Plan**

Rupiah weakening against US dollar may hamper pharmaceutical industry, including PT Indofarma Tbk (PT INAF), a state-owned enterprise. To anticipate this, PT INAF has reorganized its business plan. The company needs to recalculate selling price, production cost, and margin target as rupiah has reached nearly Rp11,000/US\$, said John Sebayang, PT INAF Finance Director. Rupiah weakening above Rp10,500/US\$ will raise cost of goods manufactured by 3-4% as 60-70% of raw materials are imported. PT INAF will postpone importing raw materials, using its inventory instead that may last until the end of 2013. As raw materials are more limited, PT INAF will stop making products with less than 10% profit margin and cross-subsidize with higher-margin products, except for generic drugs. PT INAF will temporarily produce e-catalog generic drug only. During this first semester, PT INAF has generated Rp9 billion loss while its 2013 revenue target is Rp1.4 billion.

**Person quoted (s):** John Sebayang, Finance Director, PT INAF